UCB Offloads Neurology and Allergy Meds in China for Nearly $700M
It appears that restructuring is the trend for many big pharmaceutical companies in the modern era, and Belgium-based UCB is no exception. UCB announced that it would be selling its neurology and...
View ArticleGermany to Provide 100,000 Mpox Vaccine Doses to Combat Outbreak in Africa
Germany has provided 100,000 doses of the Mpox vaccine from its armed forces to help combat the ongoing outbreak in Africa, a government spokesperson said. This contribution is expected to bring swift...
View ArticleBavarian Nordic Receives Mpox Vaccine Green Light From Singapore
Bavarian Nordic announced today that its vaccine, JYNNEOS, has been licensed by Singapore’s Health Sciences Authority (HSA) for the prevention of smallpox and mpox in individuals aged 18 and older who...
View ArticleMcKesson Invests $2.5B to Acquire Majority Stake in Florida-Based Community...
McKesson has planned to enhance its oncology platform with a significant investment of approximately $2.5 billion into the business and administrative services subsidiary of a community oncology clinic...
View ArticleSiemens Healthineers to Acquire Novartis’ European Radiodiagnostic Production...
As part of its strategy to expand PET imaging capabilities, Siemens Healthineers will acquire the radiodiagnostic production and distribution platforms affiliated with Novartis’ Advanced Accelerator...
View ArticleAllist Secures Leading Role in China’s KRAS Inhibitor Market with $21M...
Shanghai Allist Pharmaceuticals has significantly bolstered its position in China’s burgeoning KRAS inhibitor market through a strategic agreement with Jacobio Pharma. This deal, valued at...
View ArticleEmergent Bio’s Smallpox Vaccine Gains FDA Approval for Mpox
Emergent BioSolutions’ smallpox vaccine has received expanded approval from the U.S. Food and Drug Administration (FDA) for use in individuals at high risk of contracting mpox. This development led to...
View ArticleLife Sciences Voice Top Five Newsletter
Welcome to the latest edition of the Life Sciences Voice Top Five Newsletter, your source for the latest news in the life sciences industry! This week, we take a look at Eli Lilly’s anti-obesity drug...
View ArticleOnward awarded $1.1M grant from the Christopher & Dana Reeve Foundation to...
Onward Medical revealed that it has received a major grant from the Christopher & Dana Reeve Foundation to continue with BCI research. This $1.1M grant will fund increasing an existing early-phase...
View ArticleIllumina Gets Favorable Decision Regarding Grail Acquisition
In a decision expected to limit Brussels’ merger authority, American gene sequencing firm Illumina prevailed in court against the European Union’s inquiry into its $7.1 billion purchase of cancer...
View ArticleSanofi’s Tolebrutinib faces defeat in 2 out of 3 phase 3 MS trials
Sanofi has announced that tolebrutinib, a BTK inhibitor, failed in two out of three Phase 3 trials. Tolebrutinib was being evaluated across two forms of chronic neurological disorder. The HERCULES...
View ArticlePhase 2/3 of Athira Trial for Alzheimer’s Fails
Athira Pharma’s Phase 2/3 Alzheimer’s disease trial has ended in failure. The trial revealed that fosgonimeton performed no better than a placebo for the primary and several key secondary outcomes....
View ArticleGSK’s Asthma Drug Meets Primary Endpoint in Phase 3 Trial
After successfully completing two trials, SWIFT-1 and SWIFT-2, for its long-acting asthma drug depemokimab, GSK has now shared results for its Phase 3 trial. These trials demonstrated the treatment’s...
View ArticleTern’s oral GLP-1 achieves 5% weight reduction within one month at the...
Terns Pharmaceuticals’ decision to move away from the liver disease field may turn out to be beneficial since early phase 1 data suggests that another of its candidates – TERN-601 – may also be...
View ArticleRelay Wins Early on Breast Cancer, Arranges Crucial Trial Against Truqap from...
Relay Therapeutics released interim Phase I/II data showing that RLY-2608, its investigational PI3Kα inhibitor, demonstrated “clinically meaningful” progression-free survival (PFS) in patients with...
View ArticleViridian Drug Successfully Meets Study Objectives as Treatment for Thyroid...
Viridian announced that veligrotug, its potential thyroid eye disease (TED) drug, recorded impressive results in managing TED during a late-phase trial. The increase in effectiveness puts the drug in a...
View ArticleBrightflow SAS Nabs $18M For Heart Failure Solution
Brightflow SAS, a privately owned company at the forefront in the area of long-term percutaneous mechanical circulatory assistance for the treatment of patients in the latter stages of heart failure,...
View ArticleGilead and AI Drug Discovery Company Genesis Sign $35 Million Partnership
Genesis Therapeutics’ AI drug discovery platform, GEMS, has gained popularity and now attracted the attention of Gilead Sciences with a $35M partnership. In a major deal, Gilead will pay $35 million to...
View ArticleEli Lilly Sees Second Round of Positive Data on Weekly Insulin Candidate
Eli Lilly’s insulin candidate efsitora alfa has achieved its main goals in a further two trials, which belong to the QWINT phase 3 development program. These two trials, QWINT-2 and QWINT-5, mainly...
View ArticleITeos drug in combination with GSK’s Jemperli shows positive response in lung...
Results from a mid-stage clinical trial conducted by a small biotechnology company iTeos Therapeutics have revealed that when taken in combination with GSK immunotherapy Jemperli, their drug...
View Article